Get regular updates to your inbox.
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was…
China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three prior lines of treatment. The trial will include about 150 patients in China with relapsed of refractory multiple…
An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated assessment, given to medications expected to have a major impact on public health, shortens the regulatory review process…
A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes patients whose disease failed to respond to at least two proteasome inhibitors,…
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll up to 30 adult patients who received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and…
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. Findings to date from this open-label study (NCT03110822), which is being sponsored by Onco Therapeutics, showed…
A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation Myeloma Center for Advanced Research Excellence (Myeloma CARE) is being established through a $10 million gift from the…
The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 trial (NCT04613557) intends to recruit 12 patients who received two or more prior lines of treatment, including…
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data from the trial (NCT03933735), which continues to recruit participants in the U.S., showed an 80% overall response rate…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from…
Get regular updates to your inbox.